The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes of immune checkpoint inhibitors in HER2-amplified non-small cell lung cancers.
 
Raymond DeMatteo
No Relationships to Disclose
 
Debra A. Goldman
Employment - Regeneron
Stock and Other Ownership Interests - Johnson & Johnson
 
Sabrina T. Lin
No Relationships to Disclose
 
Darren J. Buonocore
Stock and Other Ownership Interests - Merck; Novartis
 
JianJiong Gao
No Relationships to Disclose
 
Jason C. Chang
No Relationships to Disclose
 
Natasha Rekhtman
Honoraria - Physicans' Education Resource
 
Michael Offin
Honoraria - OncLive
Consulting or Advisory Role - American Society for Radiation Oncology; Jazz Pharmaceuticals; Novartis; PharmaMar; Targeted Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; C4 Therapeutics; Cullinan Oncology; Daiichi Sankyo; Janssen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Blueprint Medicines; Cullinan Oncology (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Janssen Oncology (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Astellas Pharma
 
James M. Isbell
Stock and Other Ownership Interests - LumaCyte
 
David Randolph Jones
Consulting or Advisory Role - AstraZeneca; Merck
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bridge Medicines; Daiichi Sankyo/UCB Japan; Earli; Epizyme; Genentech/Roche; Harpoon Therapeutics; Ipsen; Jazz Pharmaceuticals; Kowa; Merck; Syros Pharmaceuticals; Syros Pharmaceuticals
Research Funding - Merck (Inst); Roche/Genentech (Inst)
 
William D. Travis
Consulting or Advisory Role - Genentech
Speakers' Bureau - Genentech
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca; Janssen; Pfizer
Travel, Accommodations, Expenses - Genentech
 
Alexander E. Drilon
Stock and Other Ownership Interests - Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV More; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Maria E. Arcila
Honoraria - Biocartis; Invivoscribe
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Roche
Travel, Accommodations, Expenses - AstraZeneca; Invivoscribe; Raindance Technologies
 
Michelle S. Ginsberg
No Relationships to Disclose
 
Alexia Iasonos
Stock and Other Ownership Interests - Bristol-Myers Squibb/Sanofi
Consulting or Advisory Role - BrightPath Biotheraputics; Intelligencia; Mylan
 
Dazhi Liu
Consulting or Advisory Role - InVitae
 
Bob T. Li
Research Funding - Ambrx (Inst); Amgen (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Hengrui Therapeutics (Inst); Lilly (Inst); MORE Health (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Karger Publishers - Book royalty; Shanghai Jiao Tong University Press - Book royalty; US62/514,661 (Inst); US62/685,057 (Inst)
Travel, Accommodations, Expenses - Jiangsu Hengrui Medicine; MORE Health
(OPTIONAL) Uncompensated Relationships - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Genentech; Lilly